[go: up one dir, main page]

MX9707501A - Dominio intracelular de la proteina her-2/neu para la prevencion o tratamiento de malignidades. - Google Patents

Dominio intracelular de la proteina her-2/neu para la prevencion o tratamiento de malignidades.

Info

Publication number
MX9707501A
MX9707501A MX9707501A MX9707501A MX9707501A MX 9707501 A MX9707501 A MX 9707501A MX 9707501 A MX9707501 A MX 9707501A MX 9707501 A MX9707501 A MX 9707501A MX 9707501 A MX9707501 A MX 9707501A
Authority
MX
Mexico
Prior art keywords
malignancies
prevention
treatment
intracellular domain
neu protein
Prior art date
Application number
MX9707501A
Other languages
English (en)
Other versions
MXPA97007501A (es
Inventor
Martin A Cheever
Mary L Disis
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX9707501A publication Critical patent/MX9707501A/es
Publication of MXPA97007501A publication Critical patent/MXPA97007501A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G01N33/57557—
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen compuestos y composiciones para obtener o mejorar la reactividad inmune a la proteína HER-2/neu. Los compuestos incluyen polipétidos y moléculas de ácido nicleico que condifican estos péptidos. Los compuestos se pueden usar para la prevencion o tratamiento de malignidades a las cuales se asocia el oncogeno HER-2/neu.
MXPA/A/1997/007501A 1995-03-31 1997-09-30 Dominio intracelular de la proteina her-2/neu para la prevencion o tratamiento de malignidades MXPA97007501A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/414,417 US5801005A (en) 1993-03-17 1995-03-31 Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US08414417 1995-03-31

Publications (2)

Publication Number Publication Date
MX9707501A true MX9707501A (es) 1998-06-30
MXPA97007501A MXPA97007501A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
US5846538A (en) 1998-12-08
KR100554186B1 (ko) 2007-04-11
NO974502D0 (no) 1997-09-29
CN1597953A (zh) 2005-03-23
PT817846E (pt) 2005-11-30
WO1996030514A1 (en) 1996-10-03
EP0817846A1 (en) 1998-01-14
CZ309697A3 (cs) 1998-01-14
US20020055614A1 (en) 2002-05-09
RU2236461C2 (ru) 2004-09-20
NO974502L (no) 1997-11-27
HUP9801826A3 (en) 2000-12-28
AU5522296A (en) 1996-10-16
US5726023A (en) 1998-03-10
CZ296617B6 (cs) 2006-05-17
BR9607889A (pt) 1999-08-10
RU2004115492A (ru) 2005-11-10
US20100087621A1 (en) 2010-04-08
CZ296618B6 (cs) 2006-05-17
EP1418235A2 (en) 2004-05-12
US5801005A (en) 1998-09-01
US5876712A (en) 1999-03-02
CA2216601A1 (en) 1996-10-03
CA2216601C (en) 2002-10-22
CN1183117A (zh) 1998-05-27
DE69634912D1 (de) 2005-08-11
EP0817846B1 (en) 2005-07-06
CN1150318C (zh) 2004-05-19
EP1418235A3 (en) 2004-08-11
NO20061723L (no) 1996-10-01
DK0817846T3 (da) 2005-11-07
NO321941B1 (no) 2006-07-24
US6075122A (en) 2000-06-13
KR19980703453A (ko) 1998-11-05
JP2008056679A (ja) 2008-03-13
AU708237B2 (en) 1999-07-29
ATE299180T1 (de) 2005-07-15
US7655239B2 (en) 2010-02-02
JPH11502710A (ja) 1999-03-09
US7247703B2 (en) 2007-07-24
US6664370B2 (en) 2003-12-16
US20080076904A1 (en) 2008-03-27
HUP9801826A2 (hu) 1998-11-30
ES2245783T3 (es) 2006-01-16
CN1951398A (zh) 2007-04-25
JP4510147B2 (ja) 2010-07-21
DE69634912T2 (de) 2006-04-20
NZ306616A (en) 2001-03-30
US20040082758A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
DK0817846T3 (da) Intracellulært domæne af HER-2/neu proteinet til forebyggelse eller behandling af maligniteter
NO890408L (no) 3-indolpyrodruesyre-derivater og deres farmasoeytiske anvendelse.
MX9709278A (es) Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
SV1998000153A (es) Proceso para la sintesis de 1,3-dioles
ATE114151T1 (de) Benzocyclobutyl- oder indanyl-alkyl-amino-alkyl substituierte 3-benzazepin-2-ones, verwendbar in der behandlung von kardiovaskularen krankheiten.
ES2149378T3 (es) Procedimiento para la sulfonilacion, sulfenilacion y fosforilacion de depsipeptidos ciclicos.
ES2128277T3 (es) Nuevos derivados de peptidos.
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
BRPI9715334B8 (pt) agentes estrogênicos e composição farmacêutica compreendendo os mesmos.
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
EP0709090A3 (en) Compositions for the treatment of resistant tumors
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
MY106352A (en) Hemoregulatory peptides.
PT783521E (pt) Compostos polipeptidos que contem d-2-alquiltriptofano capazes de promover a libertacao da hormona do crescimento
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DK0504335T3 (da) Fibronectinbindende peptid
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.